Abstract
Vaccine development and distribution have been at the forefront of efforts to combat the COVID-19 pandemic. As the vaccines have been widely adopted by the population, uncertainties around their effectiveness resulting from the emergence of new variants and other confounding factors make it challenging to determine their real-world impact, which is critical for understanding risk, informing public health policies, and mitigating the impact of COVID-19. We analyzed the association between time-dependent vaccination rates and COVID-19 severity for 48 states in the U.S. using Generalized Additive Models (GAMs). We controlled for additional dynamic factors such as testing rates, purpose-specific travel behaviors, underlying population immunity, and policy, and critical static factors such as comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant driven waves separately, and evaluate if there is a changing role of the potential drivers of severity over time and across waves. Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 severity across each variant wave. Results also showed that booster shots offered additional protection against severe diseases during the Omicron wave. Additionally, higher underlying population immunity based on previous infection rates are shown to be associated with reduced COVID-19 severity. Full-service restaurant visits are associated with increased COVID-19 severity for the pre-Delta and Delta waves, while office of physician visits are associated with increased COVID-19 severity for the Omicron wave. Moreover, the states with higher government policy index scores have lower COVID-19 severity. Regarding static variables, the social vulnerability index, and the proportion of adults at high risk exhibit positive associations with COVID-19 severity, while Medicaid spending per person exhibits a negative association with COVID-19 severity. Despite the emergence of new variants, vaccines remain highly effective at reducing severe outcomes of COVID-19. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and preventing burden on healthcare systems.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded the NSF RAPID Award ID 2108526, NSF Award ID 2229996, and CDC Contract #75D30120C09570.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at https://github.com/hongru94/vaccination_rate_GAMs